p23 is an Hsp90 co-chaperone located in both the cytoplasm and nucleus that stabilizes unliganded steroid receptors, controls catalytic activity of certain kinases, regulates protein-DNA dynamics and is upregulated in several cancers. We previously demonstrated that p23-overexpressing MCF-7 cells (MCF-7+p23) exhibit increased invasion without affecting the estrogen-dependent proliferative response, which suggests that p23 differentially regulates genes controlling processes linked to breast tumor metastasis. To gain a comprehensive view of the effects of p23 on estrogen receptor (ER)-dependent and -independent gene expression, we profiled mRNA expression from control versus MCF-7+p23 cells in the absence and presence of estrogen. A number of p23-sensitive target genes involved in metastasis and drug resistance were identified.
INTRODUCTION
p23 is a ubiquitous and evolutionarily conserved protein first characterized as a component of unliganded progesterone receptor complexes (1, 2) . p23 acts as a cochaperone, stabilizing the ATP-bound form of Hsp90, thereby stabilizing Hsp90 interactions with steroid receptors (SR) (3) and assisting Hsp90 in increasing the hormone binding affinities of many SRs (4) (5) (6) . p23 is required for survival in mammals because p23-null mice die perinatally and fail to undergo proper lung development due in part to decreased activity of the glucocorticoid receptor (7) . p23 regulates SR and telomerase recruitment to DNA (8) (9) (10) (11) , and stabilizes some kinases, including PKR, FAK-2, Flt3, and Raf (12) (13) (14) (15) . In addition to Hsp90-dependent events, p23 might also regulate client proteins autonomously via its innate chaperone activity (16) . There is also evidence that mammalian p23 is a cytoplasmic prostaglandin E synthetase (PGES) (17) , although this function is controversial since p23 knockout mice do not exhibit reduced PGES activity (18) . p23 has many implicated roles in cancer. We have previously demonstrated that p23 overexpression increases ligand binding to the estrogen receptor alpha (ER) and enhances ER-dependent transcriptional activation (19, 20) . We have also demonstrated that p23 overexpression in human ER-positive MCF-7 breast cancer cells promotes a transition from non-invasive into migratory and invasive cells, without affecting cell proliferation (10) .
Mechanistically, p23 selectively increases ER-target gene transcription and ER recruitment to the estrogen response element (ERE) of the metastasis-associated gene TFF1 (pS2), rather than at proliferative genes like c-myc (10).
4 p23 protein expression increases with breast tumor stage (10) and is upregulated in metastatic cancers (21, 22) . p23 also regulates of the binding and activity of the oncoprotein, telomerase (11, 23, 24) , known to impact both early and late stages of tumorigenesis including epithelial cell transformation (25) , human mammary epithelial cell immortalization (26) , and metastasis in ER-negative breast cancer cells (27, 28) . In addition, p23 desensitizes mammalian cells to treatment with the Hsp90 inhibitor and chemotherapeutic agent geldanamycin (GA), thereby protecting Hsp90 from GA inhibition and stabilizing Hsp90 client oncoproteins (15) .
Given the implicated role of p23 in cancer and the fact that a modest increase in p23 protein expression causes such strong estrogen-dependent and -independent transcriptional and functional effects on migration and invasion in MCF-7 cells (10), we further characterized the effect of p23 on global gene expression in MCF-7 cells, and examined the expression of p23 protein in primary tumor samples with appended outcome data from women with breast cancer.
MATERIALS AND METHODS

Cell Lines
MCF-7 control and MCF-7+p23 cells were cultured and hormone-starved as previously described (10) . A single MCF-7+p23 overexpressing clone (#7) was used in the experiments. Validation of selected p23-sensitive genes was performed using an independent, previously described MCF-7+p23 clone (#8) with similar results ( Figure   S1 ) (10 
Chemotherapeutic resistance assays
Cells were hormone-starved for 3 days. Media was supplemented with 0.01-1μg/mL doxorubicin hydrochloride (Adriamycin) (Sigma; D1515), 0.02-20μM etoposide (Sigma; E1383), or 0.04-40μM camptothecin (Cpt) (Sigma; C9911) for 48h and percent survival was determined in quadruplicate for each condition using the sulphorhodamine B (SRB) assay (30) . hazards models were developed to predict recurrence or mortality. Models were selected using stepwise procedures in SAS with differences in the likelihood ratio test statistics as the criteria for model selection.
Immunohistochemistry and tissue microarray analysis
RESULTS
Higher p23 protein levels cause changes in gene expression in MCF-7 cells that are also observed in invasive breast cancers
Our previous study demonstrated that a small increase in the amount of p23 protein expression caused specific estrogen-dependent and -independent changes in MCF-7 cell gene expression and function favoring tumor progression (10) . We profiled genes globally regulated by p23 using Affymetrix microarray technology ( Figure 1a ) on RNA extracted from hormone-starved control or MCF-7 cells stably expressing two-fold more p23 protein (MCF-7+p23) (10) . The analysis identified 359 known human genes sensitive to p23 levels in the absence of estrogen treatment. Of these genes, 179 were upregulated and 180 were downregulated by more than 2-fold (genes and corresponding probe sets are listed in Tables S5-6 ). cells, is also associated with breast cancer progression (36, 37) . p8 is a nuclear phosphoprotein, TM4SF1 is a tetraspanin family member implicated in cell motility, and studies in Xenopus allude to Sox3 as a tumor suppressor through its ability to bind to β-catenin and inhibit TCF-signaling (38 Figure S3 ). The same held true for pS2 and c-myc, both well characterized ER target genes. By contrast expression of AGR2 was not reduced, but rather was enhanced upon inhibition of Hsp90. This suggests that an Hsp90-sensitive pathway may repress AGR2 expression. Surprisingly, GA or 17-AAG treatments had no effect on the expression of PMP22, despite disruption of Hsp90-p23 interaction by GA ( Figure S3 ). Thus, the effect of p23 on PMP22 gene expression appears Hsp90-independent. Collectively, these data demonstrate that p23 protein levels can modulate the expression of genes misregulated in advanced breast cancers and that certain p23-sensitive changes in gene expression are Hsp90-independent.
We also found that 357 genes were sensitive to the ER agonist 17-β-estradiol (E2)
in MCF-7 cells, many of which became more or less responsive to E2 by p23 overexpression ( Figure 1d , Figure S4 , Table S7 Gene ontology of the genes induced by p23 revealed that p23 overexpression particularly affects the expression of genes involved in metabolism (Table S3) bottom panels). The ABCC3 promoter has basal levels of histone acetylation, which can be detected above background (non-specific IgG) levels in control cells (Figure 2b ). This suggests that a mechanism of p23-mediated transcriptional activation is through increased recruitment of chromatin modifying enzymes that hyperacetylate histone H3-K9/14 and re-initiate gene transcription from active promoters.
Downregulation of PMP22 and ABCC3 gene expression by E2 is associated with ER recruitment to distal EREs
Our microarray data revealed that many genes positively regulated by p23 
High p23 expression correlates with shorter disease-free survival times in breast cancer patients
Since breast cancer cells that express more p23 have a higher invasive potential and are more drug resistant, we suspected that patients expressing high levels of p23
protein would have shorter periods of disease-free survival. We analyzed 213 specimens from a human breast tissue microarray for intensity of p23 staining in the nucleus and cytoplasm on a scale of 0 to 3, with 3 being the highest intensity staining ( Figure S6 ).
Using univariate analysis we determined associations between cytoplasmic p23, nuclear p23, stage, and tumor size (T), nodal involvement (N) and metastasis (M) (TNM status). We find that cytoplasmic p23 is significantly associated with nuclear p23 1 ). This is consistent with our observation that MCF-7+p23 cells are more migratory and invasive than control MCF-7 cells (10).
We used Cox proportional hazards models for each variable individually to examine the association of that variable with recurrence or death ( Table 2) 
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We find that "active" histone modifications (H3-AcK9/14) are present at the promoters of p23-sensitive genes (Figure 2b-c) . The fact that these modifications are also present at the promoters of some p23-sensitive genes in MCF-7 control cells where p23 is not overexpressed (Figure 2b ) indicate that p23 may not need to overcome the transcriptional barriers associated with gene silencing in order to upregulate gene expression. Therefore, a mechanism p23 may use to increase gene expression could be to recruit HATs implicated in transcription re-initiation (i.e. GCN5), rather than those involved in transcription initiation (i.e. p300) (45) to raise the transcriptional output from already "active" promoters. Akt is a potent survival signal, our findings also suggest that tumors overexpressing p23
would have a survival advantage (48) . Therefore, we propose that cancers with high levels of p23 activate signaling pathways in the cytoplasm, which can also amplify p23-sensitive gene transcription in the nucleus.
Our findings strongly suggest that individuals with breast cancers that display high p23 protein levels are more likely to exhibit lymph node involvement and experience disease recurrence and mortality. This is consistent with our in vitro model that p23 overexpression elicits gene expression and phenotypic changes in MCF-7 cells akin to those that occur as breast tumors become invasive. Given that nodal status is the most significant factor in predicting survival (49) , it will be important to find ways to reduce p23 expression to decrease lymph node metastases. Lowering p23 expression should also mitigate p23-mediated chemotherapeutic resistance (etoposide, doxorubicin).
Recently, celastrol, the active compound in "Thunder of God Vine" root extracts used in traditional Chinese medicine, has been shown to bind and inactivate p23 by triggering its 
